Cite
HARVARD Citation
Virabhak, S. et al. (2017). Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. Journal of medical economics. pp. 1144-1156. [Online].